Jan 2014

genmab

Joint Lead Manager

USD 998 million

Accelerated Bookbuild Offering

Genmab

Genmab is a Danish listed biotech company specialising in differentiated human antibody therapeutics for the treatment of cancer

Genmab raised new capital to fund the further development of in-house drug candidate HuMax-Tissue Factor-ADC and other programs
Kempen & Co was engaged as Joint Lead Manager and supported the company in one of the largest European Life Sciences ECM transactions of the past year